Valo Therapeutics Announces Scientific Advisory Board
Helsinki, Finland, 2nd August 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced four appointments to its Scientific Advisory Board (SAB), Professor Paolo A. Ascierto, Dr Jeffery Bockman, Dr Malcolm K. Brenner, and Professor Kevin Harrington.
